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Abstract: The aim of our study is to determine whether chronic obstructive pulmonary disease 
(COPD) is an independent risk factor for ischemic heart disease and whether this association is 
related with a greater prevalence of classical cardiovascular risk factors. Ours is a case-control 
cross-sectional study design. Cases were hospital patients with ischemic heart disease in stable 
phase, compared with control hospital patients. All patients underwent post-bronchodilator (PBD) 
spirometry, a standardized questionnaire, and blood analysis. COPD was defined as per GOLD 
PBD forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) , 0.70. 
In our series of patient cases (n = 204) and controls (n = 100), there were 169 men in the case 
group (83%) and 84 in the control group (84%). Ages were 67 and 64 years, respectively 
(P , 0.05). There were no significant differences by weight, body mass index (BMI), pack-
years, leukocytes, or homocysteine. The abdominal perimeter was significantly greater in cases 
(mean 101 cm ± standard deviation [SD] 10 versus 96 cm ± 11; P , 0.000). Both groups also 
had significant differences by C-reactive protein (CRP), fibrinogen, and hemoglobin values. 
In univariate analysis, increased risks for cases to show with individual classical cardiovascular 
risk factors were seen, with odds ratio (OR) 1.86 and 95% confidence interval (CI) (1.04–3.33) 
for diabetes mellitus, dyslipidemia (OR 2.10, 95% CI: 1.29–3.42), arterial hypertension   
(OR 2.47, 95% CI: 1.51–4.05), and increased abdominal perimeter (OR 1.71, 95% CI: 1.06–2.78). 
Percent predicted PBD FEV1 was 97.6% ± 23% in the patient group and 104% ± 19% in the 
control group (P = 0.01), but the prevalence of COPD was 24.1% in cases and 21% in controls. 
Therefore, COPD was not associated with ischemic heart disease: at the crude level (OR 1.19, 
95% CI: 0.67–2.13) or after adjustment (OR 1.14, 95% CI:0.57–2.29). In conclusion, COPD was 
not associated with ischemic heart disease. The greater prevalence of classical cardiovascular 
risk factors in COPD patients could explain the higher occurrence of ischemic heart disease 
in these patients.
Keywords: chronic obstructive pulmonary disease, cardiovascular disease, systemic inflam-
mation, comorbidity
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
  mortality throughout the world. It is currently considered the fourth most common 
cause of death, and the burden it generates on health care systems is enormous.1 
Comorbidities are frequent throughout the lifespan of COPD patients, and are ultimately 
responsible for many deaths. In COPD patients admitted to hospital, for severe cases, 
respiratory failure is the most common cause of death, and for mild and moderate cases, 
  cardiovascular disease (CVD) and lung cancer rank high as causes of death.2 International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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It is a research priority to establish whether there is a 
common pathogenesis of CVD and COPD, or whether these 
are associated but independent processes.3 A   number of articles 
have been recently published highlighting systemic inflam-
mation in COPD patients and suggesting that   inflammation 
could favor the appearance of atherosclerotic disease in COPD 
patients.4,5 This theory would assume a causal relationship of 
COPD in CVD. However, there are no definitive data yet to 
confirm that chronic airflow obstruction, and its accompanying 
systemic inflammation, causes CVD.
Different studies have demonstrated that forced expiratory 
volume in the first second (FEV1) is a predictor of coronary 
disease in smokers as well as in nonsmokers.6 Supporting 
this, several observational studies published in the last two 
decades have reported an association between a reduction 
of FEV1 and increased cardiovascular risk. They are further 
supported by findings in more basic studies that directly 
analyze vascular damage by means of magnetic resonance, 
tomography, or ultrasound.7–9 However, this association is not 
as straightforward in clinical studies with standard spirom-
etry confirming a COPD diagnosis by a post-bronchodilator 
(PBD) FEV1/forced vital capacity (FVC) ratio less than 0.70 
has not always been confirmed. Briefly, other risk factors 
were not adequately evaluated; in some cases, symptoms 
of bronchitis without spirometry were taken into account, 
and in others the COPD definition was based on having 
been labeled by International Classification of Diseases, 9th 
Edition (ICD-9) codes for COPD, emphysema, or chronic 
bronchitis, but without spirometric confirmation.6,10,11
In a recent observational study carried out in our   setting, 
we found that COPD patients present a prevalence of car-
diovascular risk factors greater than that reported in the 
general population for similar age strata; a higher preva-
lence of CVD was likewise observed, but although age and 
classic   cardiovascular risk factors were related to increased 
  cardiovascular morbidity, we did not observe a relationship 
between CVD severity and airflow limitation.12
The objective of this research is to determine, by means 
of a case-control study, whether COPD is an independent 
risk factor of ischemic heart disease, or whether the increase 
in CVD observed in COPD patients is related to classical 
cardiovascular risk factors.
Material and methods
study population
Ours is a case-control cross-sectional study of subjects 
that met the inclusion criteria described in Table 1. The 
study population domain included patients aged 40 years 
and older in the outpatient consultations and the cardiol-
ogy unit (for cases), and from the surgical waiting lists 
of ophthalmology for cataracts and traumatology for knee 
prosthesis (for controls). All participating patients were 
considered to be in a stable phase for at least 1 month 
prior to recruitment. Given that in our setting COPD is 
still a far less frequent disease in women than men, refer-
ence control group was frequency-matched to the gender 
and age distribution of cases. The flow chart of patients 
considered to participate in the study is presented in 
Figure 1. This study followed the Strobe statement for 
observational studies.13
ethical considerations
This study was conducted in accordance with the ethi-
cal principles established in the Declaration of Helsinki 
(Edinburgh revision, 2000). In the first visit, and prior 
to data collection, all study subjects gave their informed, 
written consent. The study was approved by the Ethics and 
Clinical Research Committee of the Hospital Universitario 
of Guadalajara.
Table 1
Inclusion criteria
Male and female patients older than 40.
Cases: patients with ischemic heart disease, meaning those patients who 
within the last 12 months had at least one episode of:
 •     stable angor pectoris: characteristic chest pain during exertion that 
subsides with rest, sublingual nitrates, or both. These patients must 
have a positive exercise stress test.
 •   Unstable angor pectoris:
    1.   Patients with recent-onset angina (,2 months), that has become 
more severe and frequent (.3 episodes per day);
    2.   Patients with stable angina that is clearly becoming more 
frequent, severe, prolonged, or is triggered with less intensive 
exercise than before;
    3. Patients with angina of any type that occurs while at rest.
 •     Acute myocardial infarction: defined as per WHO criteria with at 
least two of the following three criteria: characteristic chest pain, 
increase in myocardial injury markers, and eKg changes.
Controls: hospital patients with no history of ischemic heart disease, 
frequency matched to similar age and gender to the case group.
Exclusion criteria
Patients with chronic or acute liver disease.
Patients with diseases that cause an increase in inflammatory markers:
 •   Infectious disease
 •   Chronic inflammatory disease
 •   Traumatism, post-surgery, burns, fractures
 •   neoplasia
 •   Patients undergoing hemodialysis International Journal of Chronic Obstructive Pulmonary Disease  2010: 5
Identification of cases 
N = 214 
Identification of controls 
N = 116 
Patients who accepted* 
N = 204 
Appointment made in stable 
phase 
Spirometry, 
blood analysis, 
standardized questionnaire 
Patients who accepted** 
N = 100 
Appointment made in stable 
phase
Spirometry, 
blood analysis, 
standardized questionnaire 
Cardiology ward 
Cardiology consultation 
Traumatology waiting list 
Ophthalmology waiting list
Figure 1 Flow chart of participants.
Notes: *10 patients in case group declined to participate; **16 patients in control group declined to participate; In both cases these patients were changed for subjects with 
similar age and the same sex.
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Diagnostic tests
In all participants, a blood sample was obtained 
to measure inflammatory markers (high-sensitivity 
C-reactive protein [SCRP] and fibrinogen, hemogram, 
glucose, homocysteine, and blood cholesterol). Standard 
spirometry was performed, and tests were repeated again 
30 minutes after administering 400 µg of salbutamol and 
80 µg of ipratropium bromide. Spirometries were carried 
out in accordance with current international quality stan-
dards with a spirometer (Masterlab; Jaeger, Hoechberg 
Germany). COPD was defined as a PBD FEV1/FVC ratio 
of less than 0.70 (GOLD and American Thoracic Society/
European Respiratory Society criteria.1,15 Finally, study 
subjects completed a standardized questionnaire on clini-
cal data, smoking data, drug treatments, and concomitant 
diseases.
sample size
Considering an expected prevalence of GOLD-defined 
COPD in controls of 9%, and expecting a three-fold 
higher frequency of COPD in cases, given an alpha 
error of 5% and power of 90%, we required 200 cases 
and 100 controls to obtain statistical significance.16,17 
Calculations assuming larger prevalences of COPD in 
controls or lower in cases would result in more power-
ful statistics. International Journal of Chronic Obstructive Pulmonary Disease 2010:5
Table  2  Demographic,  clinical  characteristics,  and  selected       
biochemistry for cases and controls
Cases (204) Controls (100) P
Age 67 (10) 64 (9) ,0.05
Male (%) 169 (83%) 84 (84%)
Weight (Kg) 76 (13) 78 (12) 0.26
BMI (Kg/m2) 27.7 (4.8) 28.2 (4.3) 0.44
smokers n (%) 149 (73%) 66 (66%)
  Current 32 (16%) 32 (32%)
  ex-smokers 117 (57%) 31 (31%)
nonsmokers 55 (27%) 34 (34%)
Pack/year 33 (25) 37 (23) 0.24
Abdominal perimeter (cm) 101 (10) 96 (11) 0.000
Abdominal perimeter* 115 (56.4%) 43 (43%) 0.028
Diabetes mellitus 62 (30.4%) 19 (19%) 0.035
Dyslipidemia 117 (57.4%) 39 (39%) 0.003
Arterial hypertension 123 (60.3%) 38 (38%) 0.000
FeV1 post (L) 2.66 (0.75) 2.88 (0.88) 0.05
FeV1 post (%) 97.6 (23) 104 (19) 0.01
FVC post (L) 3.44 (0.89) 3.79 (1.24) 0.01
FVC post (%) 104 (20) 109 (19) 0.04
FeV1/FVC post (%) 76 (11) 79 (10) 0.02
CrP (mg/L) 4.80 (7.89) 2.75 (2.85) 0.001
hemoglobin (g/dl) 14.2 (1.5) 15.3 (1.6) 0.000
Leukocytes (x1000/l ) 7.73 (2.15) 7.62 (2.2) 0.67
homocysteine (µmol/L) 12.07 (5) 12.9 (5) 0.18
Fibrinogen (mg/dL) 338 (91) 298 (67) 0.000
Note: *number of subjects with abdominal perimeter greater than 102 cm in men 
and 88 cm in women (16).
Abbreviations:  BMI,  body  mass  index;  CrP,  C-reactive  protein;  FeV1,  forced 
expiratory volume in the first second; FVC, forced vital capacity.
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Data analysis
Initially, a statistical descriptive analysis of crude data and 
in-depth quality control was conducted. Continuous data are 
presented as means and standard deviation (SD) or with 95% 
confidence intervals (CIs). Differences by groups were ana-
lyzed with Student’s t-test for unpaired samples, or using the 
chi-squared test for dichotomous variables. A P value lower 
than 0.05 was considered significant. To estimate the mag-
nitude of the effect or the association, we used the odds ratio 
(OR) as the ratio between the odds of exposure (ie, COPD) 
observed in cases versus the one in controls. Likewise, we cal-
culated the corresponding confidence interval of the OR.
Finally, a logistic regression analysis was undertaken to 
evaluate the effect of covariates on the response variable, 
adjusting for confounding factors.
Results
We studied a series of 204 patient cases with ischemic 
heart disease and 100 controls, whose gender distribution 
was similar by design (male 83% versus 84%). Ages were 
67 and 64 years, respectively (P , 0.05). In addition, no 
significant differences by weight, body mass index (BMI), 
pack-years, leukocytes, or homocysteine were observed. The 
abdominal perimeter was significantly greater in cases (mean 
101 cm ± SD 11 versus 96 cm ± 11; P , 0.000), and using a 
cutoff of 88 cm in women and 102 cm in men, this difference 
persisted for the number of patients who presented a greater 
abdominal perimeter in the CVD group compared with the 
control group, although as mentioned above, weight and BMI 
were not statistically different (Table 2).18
Both groups had also significant differences in CRP, 
fibrinogen, and hemoglobin values. In univariate analysis, 
increased risks with individual classical cardiovascular risk 
factors were seen, with OR 1.86 and 95% CI (1.04–3.33) for 
diabetes mellitus, dyslipidemia (OR 2.10, 95% CI: 1.29–3.42), 
arterial hypertension (OR 2.47, 95% CI: 1.51–4.05), 
prior smoking history (OR 1.39, 95% CI: 0.83–2.34), 
overweight (OR 1.24, 95% CI: 045–3.30), moderate obesity 
(OR 1.69, 95% CI:  0.67–4.30), severe obesity (OR 1.71, 95% 
CI: 0.63–4.68), and increased abdominal perimeter (OR 1.71, 
95% CI: 1.06–2.78). After adjustment, age, arterial hyper-
tension, abdominal perimeter, obesity, and treatment with 
statins remained significant (Table 3). Percent predicted PBD 
FEV1 was 97.6% ± 23 in the patient group and 104% ± 19 in 
the control group (P = 0.01), but the prevalence of COPD 
was 24.1% in cases and 21% in controls. Therefore, COPD 
was not associated with ischemic heart disease at the crude 
level (OR 1.19, 95% CI: 0.67–2.13) or after adjustment by 
cardiovascular risk factors (OR 1.19, 95% CI: 0.57–2.29). 
Most of COPD were mild and moderate according to GOLD 
criteria. Only four patients had a FEV1 below 50%. Our plan 
Table 3 Crude and adjusted Ors (95% CI) for classical cardiovas-
cular risk factors and COPD defined according to GOLD
Crude  
OR (95% CI)
Adjusted  
OR (95% CI)
Age 1.41 (0.87–2.28) 1.03 (1.00–1.06)
Male (%) 1.48 (0.48–1.75) 1.51 (0.62–3.66)
smoker n (%) 1.39 (0.83–2.34) 1.71 (0.88–3.36)
Diabetes mellitus 1.86 (1.04–3.33) 0.65 (0.33–1.27)
Arterial hypertension 2.47 (1.51–4.05) 2.14 (1.17–3.89)
Dyslipidemia 2.10 (1.29–3.42) 0.97 (0.50–1.90)
high abdominal perimeter  1.71 (1.06–2.78) 2.81 (1.45–5.47)
Obesity: (BMI: 25–30) 
          (BMI: 30–35) 
          (BMI: $35)
1.24 (0.45–3.30) 
1.69 (0.67–4.30) 
1.71 (0.63–4.68)
2.27 (0.67–7.72) 
3.97 (1.22–12.92) 
8.70 (2.24–33.7)
Treatment with statins 0.44 (0.30–0.62) 0.22 (0.11–0.44)
COPD  1.19 (0.67–2.13) 1.14 (0.57–2.29)
Abbreviations: BMI, body mass index (Kg/m2); OR, odds ratio; CI, confidence 
interval; COPD, chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease  2010: 5 submit your manuscript | www.dovepress.com
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did not propose an analysis with different levels of severity, 
and our sample size does not allow such analysis.
Discussion
The most relevant finding of our study is that COPD, defined 
as a PBD FEV1/FVC ratio of less than 70%, was not associ-
ated with ischemic heart disease. Although patients with 
ischemic heart disease had significantly lower lung function 
than controls, they also had more often classical cardiovascu-
lar risk factors. The classical cardiovascular risk factors were 
associated with an increase in CVD disease, but a decrease 
in lung function was not.
Previous studies
In a recent observational study carried out in our setting, 
COPD patients presented a greater prevalence of cardiovas-
cular and ischemic cardiopathy risk factors than the general 
population. We did not observe, however, a direct relation-
ship with the deterioration of FEV1 or with having been 
diagnosed with COPD using spirometric criteria.12 Our data 
had the limitations inherent of observational studies and can 
therefore only be considered exploratory. These limitations 
should be extrapolated to all observational studies published 
to date. Recently, Johnston et al have reported an association 
between poor lung function and greater cardiovascular risk in 
a population-based study.19 However, when the results were 
adjusted for other classical risk factors such as age, sex, race, 
hypertension, diabetes, cholesterol, fibrinogen and tobacco 
habit, the association between lung function and cardiovas-
cular risk held fast only with the restrictive patients in the 
nonsmoker group, with the restrictive patients and COPD 
stages 2–4 in the group of ex-smokers, and with none of the 
active smokers. It is necessary to keep in mind that although 
the adjustment for other variables that could generate con-
fusion was notable, these adjustments present limitations 
as they did not include other vascular risk factors, such as 
lack of physical activity, obesity, alcohol intake, poor diet, 
or presence of sleep respiratory disorders, whose relevance 
has yet to be determined in COPD patients. In addition, it 
is extremely difficult in observational studies to evaluate 
how these factors interrelate.20 For example, tobacco habit, 
which is practically constant in these patients, in addition 
to being independently related to cardiovascular disease, is 
also associated with an increase in blood pressure. Moreover, 
the limited physical activity that these patients frequently 
develop can lead to excess weight gain, a situation which 
occurs in more than 50% of our COPD population.21 Taking 
into account the limitations of observational studies, and until 
prospective longitudinal studies are completed, case-control 
studies can augment our information in this area.
In a study of cases and controls done in the United King-
dom with 2699 COPD patients (46% active smokers), the 
patients presented a greater number of comorbidities than 
asthma patients. This study was not adequately adjusted for 
other risk factors, so it is therefore not possible to evaluate the 
impact of COPD on the cardiovascular risk of these patients.22 
In another series of cases and controls, the COPD patients had 
a greater history of tobacco habit and a greater prevalence 
of cardiovascular pathologies, heart failure, neoplasia, and 
neurological and digestive pathologies (3.7 chronic processes 
in the COPD group versus 1.8 in the control group).23 Lastly, 
in a retrospective study completed in Canada with a cohort 
of patients diagnosed with COPD, Curkendall et al found 
that after adjusting for cardiovascular risk factors, the degree 
of severity of the disease, established according to clinical 
criteria, constituted a risk factor for the presentation of 
myocardial infarction and death due to CVD.24 Neverthe-
less, the case definition included a heterogeneous group of 
patients including those diagnosed with COPD, emphysema, 
or chronic bronchitis in accordance with the ICD-9, but with 
no spirometric evaluation following the GOLD criteria.
From another point of view, Soriano et al have described 
recently that the prevalence of airflow limitation (AL) in 
patients with CVD was substantial and that most of these 
patients were not diagnosed appropriately.25 However, they 
found that the prevalence of AL in population participants 
with CVD (19.2%; 95% CI: 8.1–30.7) was only slightly 
higher than that of population participants without it (17.5%; 
95% CI: 14.0–21.0) (P . 0.05).23 This prevalence is quite 
similar to that observed in our study.
Interpretation of findings
Unlike the reports of other studies, we have not observed a 
direct relationship between the presence of GOLD spirometric 
COPD criteria and a presence of cardiovascular complica-
tions. On the contrary, we did find that obesity, abdominal 
perimeter, or high blood pressure, diabetes mellitus, and dys-
lipemia constituted risk factors for ischemic cardiopathy.
Although slightly lower values of FEV1 and FVC were 
observed in CVD patients when compared with the control 
group, various factors can explain these findings and our 
discrepancy with previous series, as follows:
1.  COPD spirometric criteria (PBD FEV1/FVC ratio , 70%) 
is arbitrary and does not necessarily reflect the existence  International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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of a real disease. In fact, when the prevalence of COPD 
is evaluated in population studies, the actual impact of 
COPD can be drastically reduced when the lower limit 
of normal (LLN) is used.26–28 Any study that uses GOLD 
criteria can be conditioned by the limited clinical relevance 
of the FEV1/FVC ratio in certain senior age population 
groups. In our series, the prevalence of COPD by GOLD 
criteria was greater than in the general Spanish population, 
but the difficulty of properly evaluating these values has 
recently been demonstrated in a study carried out in our 
country, mostly in older populations. Not surprisingly, 
prevalence by LLN criteria was lower in both groups, but 
the difference between both groups was greater.29
2.  Reduced spirometric volumes are not always associated with 
airflow obstruction. In a recent population study completed 
in Paris with 121,965 subjects, an association was observed 
between deterioration in lung function and the presence of 
metabolic syndrome, which was related to the increase in 
abdominal perimeter, regardless of age, sex, tobacco habit, 
alcohol consumption, level of education, BMI, physical activ-
ity, or history of CVD.30 This increase in abdominal perimeter 
is a well known cardiovascular risk factor. The reduction of 
FVC that was observed in this study can lead to restrictive 
spirometries or accentuate the functional deterioration (FEV1 
and FVC) in obstructive patients. In these cases, the decrease 
in spirometric values would only be an epiphenomenon, 
and our interpretation that the obstruction of the airflow is a 
risk factor “per se” would be erroneous.31 In our series, we 
observed an inverse relationship between FEV1 and FVC 
values and abdominal perimeter; these data suggest that this 
aspect can be relevant in explaining the association between 
functional deterioration and the risk for CVD.
3.  COPD could favor cardiovascular risk, but due to mecha-
nisms that are collateral to the obstruction itself and not 
necessarily due to a mechanism of systemic inflammation 
produced by the obstructive disease. During the last few 
years, it has been proposed that COPD could produce 
systemic inflammation and that this inflammation could 
be the link between COPD and an increase in CVD in 
these patients.32 In this sense, more attention has been 
centered on CRP. Although COPD patients can present 
higher CRP values, various factors can condition this 
increase.33 In a study by Aronson, the highest levels of 
CRP in COPD patients were in those who presented 
associated obesity.34 In addition to excess weight, other 
factors that are frequently observed in COPD patients, 
such as an abdominal fat mass or sedentary lifestyle, can 
elevate CRP values in addition to being related with a 
greater risk for metabolic syndrome.21,35–37 It is therefore 
not surprising that COPD patients have more CVD, as 
there are multiple cardiovascular risk factors associated 
with the disease, but when this increase in risk is adjusted 
for the classical cardiovascular risk factors, an additional 
effect of airway obstruction is not confirmed.
study limitations
The prevalence of cardiovascular risk factors is not uniform 
among countries. Diet and lifestyle in the Mediterranean 
population have possibly influenced the results and may limit 
the extrapolation of these results to other geographical areas. 
Given that neither observational studies nor those of cases 
and controls would allow for this factor to be adequately 
adjusted, only the completion of longitudinal studies in dif-
ferent settings would make this clarification.
The size of the sample does not exclude definitively that 
there is a weak effect of COPD on the CVD. However, our 
data do not support that COPD is a relevant risk factor and, if 
any, it would be a small one. Only a longitudinal study with 
sufficient person–time experience can answer this question 
properly. We were indeed concerned with sample size, as ours 
is a single-center study. A posteriori, after an interim analysis, 
we estimated it was not worth increasing further our obtained 
sample, as the power gain would have been little.
One possible risk in the study of these characteristics is 
the generation of selection bias due to lack of patient col-
laboration. To correct this factor, when pre-selected patients 
refused participation in the study, various attempts were made 
to convince said subjects to participate. When this was not 
possible, another patient with similar age and sex character-
istics was selected as a replacement.
For controls, we used other hospital patients within our 
domain catchment population. Given our interest in an aging 
population, we considered that other options such as using 
a general population sample might have led to an excessive 
number of failures and a potential responder bias.   Hospital 
patient bias (Berkson’s bias) may occur when hospital controls 
are used in a case-control study. If the controls (ophthalmic 
and trauma outpatients) are hospitalized due to exposure that 
is also related to the disease under study (COPD) then the 
measure of effect may be weakened, ie, biased towards the null 
hypothesis of no association. It is highly unlikely that CVD or 
COPD, our prime interest, were the reason for consultations in 
our ophthalmic or trauma patients. Therefore, we believe that 
controls are appropriate for the purpose of the study, because 
all information indicate a priori that it does not affect for a 
greater or lesser prevalence of COPD within groups. International Journal of Chronic Obstructive Pulmonary Disease  2010: 5 submit your manuscript | www.dovepress.com
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Finally, as this study was of cases and controls, it can be dif-
ficult to establish the time sequence between exposure and the 
disease, but given that COPD is a disease with a long evolution, 
we consider this situation to be infrequent. However, the lack 
of a longitudinal follow-up can condition the proper evalua-
tion of the impact of different CVD risk factors. For the same 
reason, other risk factors such as physical activity or alcohol 
intake were not included in the analysis. In a nonlongitudinal 
study, the impact of treatment on risk could not be adequately 
evaluated between the two groups despite our observation of 
a significant relation with the use of statins.
In conclusion, in this study of cases (patients with 
ischemic cardiopathy) and control subjects (those without 
ischemic cardiopathy), carried out in a Mediterranean popula-
tion, we have not observed that COPD diagnosis according 
to GOLD criterion conditions greater vascular risk when 
adjusted for classic risk factors.
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